379 related articles for article (PubMed ID: 30118848)
1. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
[TBL] [Abstract][Full Text] [Related]
2. A Novel Camptothecin Derivative 3j Inhibits Nsclc Proliferation Via Induction of Cell Cycle Arrest By Topo I-Mediated DNA Damage.
Liu Y; Zhang J; Feng S; Zhao T; Li Z; Wang L; Wang P; Du H; Yuan S; Sun L
Anticancer Agents Med Chem; 2019; 19(3):365-374. PubMed ID: 30523769
[TBL] [Abstract][Full Text] [Related]
3. A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors.
Miao Z; Zhu L; Dong G; Zhuang C; Wu Y; Wang S; Guo Z; Liu Y; Wu S; Zhu S; Fang K; Yao J; Li J; Sheng C; Zhang W
J Med Chem; 2013 Oct; 56(20):7902-10. PubMed ID: 24069881
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
Liu W; Zhu L; Guo W; Zhuang C; Zhang Y; Sheng C; Cheng P; Yao J; Wang W; Dong G; Wang S; Miao Z; Zhang W
Eur J Med Chem; 2011 Jun; 46(6):2408-14. PubMed ID: 21463912
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Evaluation of 10-Substituted Camptothecin Derivatives with Improved Water Solubility and Activity.
Yang XY; Zhao HY; Lei H; Yuan B; Mao S; Xin M; Zhang SQ
ChemMedChem; 2021 Mar; 16(6):1000-1010. PubMed ID: 33241878
[TBL] [Abstract][Full Text] [Related]
7. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
8. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Huang M; Gao H; Chen Y; Zhu H; Cai Y; Zhang X; Miao Z; Jiang H; Zhang J; Shen H; Lin L; Lu W; Ding J
Clin Cancer Res; 2007 Feb; 13(4):1298-307. PubMed ID: 17287296
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells.
Wang Y; Yang L; Zhang J; Zhou M; Shen L; Deng W; Liang L; Hu R; Yang W; Yao Y; Zhang H; Zhang Z
Int J Oncol; 2018 Oct; 53(4):1667-1680. PubMed ID: 30085332
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.
Yao L; Zhao X; Li Q; Zu Y; Fu Y; Zu B; Meng X; Liu C
Int J Pharm; 2012 Feb; 423(2):586-8. PubMed ID: 22193057
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
Wang MJ; Liu YQ; Chang LC; Wang CY; Zhao YL; Zhao XB; Qian K; Nan X; Yang L; Yang XM; Hung HY; Yang JS; Kuo DH; Goto M; Morris-Natschke SL; Pan SL; Teng CM; Kuo SC; Wu TS; Wu YC; Lee KH
J Med Chem; 2014 Jul; 57(14):6008-18. PubMed ID: 25003995
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors.
Zhu L; Cheng P; Lei N; Yao J; Sheng C; Zhuang C; Guo W; Liu W; Zhang Y; Dong G; Wang S; Miao Z; Zhang W
Arch Pharm (Weinheim); 2011 Nov; 344(11):726-34. PubMed ID: 21956522
[TBL] [Abstract][Full Text] [Related]
14. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin.
Yang CJ; Li B; Zhang ZJ; Gao JM; Wang MJ; Zhao XB; Song ZL; Liu YQ; Li H; Chen Y; Lee KH; Morris-Natschke SL; Xu C
Eur J Med Chem; 2020 Feb; 187():111971. PubMed ID: 31881457
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological assays of 9-(acylamino) homocamptothecins as DNA topoisomerase I inhibitors.
Guo W; Dong G; Zhu L; Liu W; Zhuang C; Guo Z; Yao J; Sheng C; Zhang H; Miao Z; Zhang W
Chem Biodivers; 2013 Oct; 10(10):1804-15. PubMed ID: 24130024
[TBL] [Abstract][Full Text] [Related]
17. RECQL5 is an important determinant for camptothecin tolerance in human colorectal cancer cells.
Wang X; Lu X; Zhou G; Lou H; Luo G
Biosci Rep; 2011 Oct; 31(5):363-9. PubMed ID: 21210765
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.
Zhu L; Zhang X; Lei N; Liu W; Miao Z; Zhuang C; Sheng C; Guo W; Dong G; Yao J; Cheng P; Zhang W
Chem Biodivers; 2012 Jun; 9(6):1084-94. PubMed ID: 22700227
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and antitumor activity of non-camptothecin topoisomerase I inhibitors.
Zhang C; Li S; Ji L; Liu S; Li Z; Li S; Meng X
Bioorg Med Chem Lett; 2015 Oct; 25(20):4693-6. PubMed ID: 26384290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
